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Abstract
Human lysozyme is a key component of the innate immune system, and recombinant forms of the enzyme represent
promising leads in the search for therapeutic agents able to treat drug-resistant infections. The wild type protein, however,
fails to participate effectively in clearance of certain infections due to inherent functional limitations. For example, wild type
lysozymes are subject to electrostatic sequestration and inactivation by anionic biopolymers in the infected airway. A
charge engineered variant of human lysozyme has recently been shown to possess improved antibacterial activity in the
presence of disease associated inhibitory molecules. Here, the 2.04 A˚ crystal structure of this variant is presented along with
an analysis that provides molecular level insights into the origins of the protein’s enhanced performance. The charge
engineered variant’s two mutated amino acids exhibit stabilizing interactions with adjacent native residues, and from a
global perspective, the mutations cause no gross structural perturbations or loss of stability. Importantly, the two
substitutions dramatically expand the negative electrostatic potential that, in the wild type enzyme, is restricted to a small
region near the catalytic residues. The net result is a reduction in the overall strength of the engineered enzyme’s
electrostatic potential field, and it appears that the specific nature of this remodeled field underlies the variant’s reduced
susceptibility to inhibition by anionic biopolymers.
Citation: Gill A, Scanlon TC, Osipovitch DC, Madden DR, Griswold KE (2011) Crystal Structure of a Charge Engineered Human Lysozyme Having Enhanced
Bactericidal Activity. PLoS ONE 6(3): e16788. doi:10.1371/journal.pone.0016788
Editor: Claudine Mayer, Institut Pasteur, France
Received August 25, 2010; Accepted January 14, 2011; Published March 7, 2011
Copyright:  2011 Gill et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Wallace H. Coulter Foundation (http://www.whcf.org/) Early Career Award, a Cystic Fibrosis Foundation (http://www.cff.
org/) Carol Basbaum Memorial Postdoctoral Fellowship (SCANLO08F0), and P20RR018787-06 from the National Center for Research Resources (NCRR), a
component of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: KEG and TCS have filed a patent application on the therapeutic applications of the engineered human lysozyme. PCT/US10/21363
entitled ‘‘Therepeutic Charge Engineered Variants of Lysozyme and Methods for Using the Same to Treat Infections’’ was filed on January 16, 2010. This patent
application does not alter the authors’ willingness to adhere to all the PLoS ONE policies on sharing data and materials.
* E-mail: Karl.E.Griswold@Dartmouth.edu
¤ Current address: Bio-Architecture Lab, Berkeley, California, United States of America
Introduction
Chronic pulmonary infections are a major cause of patient
morbidity and mortality in diseases ranging from cystic fibrosis
(CF) to chronic obstructive pulmonary disease (COPD) and
pneumonias. In CF, polymicrobial airway infections are estab-
lished early, and by adulthood most patient airways are
persistently colonized by the opportunistic pathogen Pseudomonas
aeruginosa, the primary cause of patient mortality [1]. Although a
complete understanding of CF pathology remains elusive, it is
thought that increased viscoelasticity of the airway surface liquid
and reduced mucociliary clearance facilitate the establishment of
chronic bacterial infections [2]. In addition to physiological factors
that favor the persistent nature of CF infections, drug-resistance is
a critical issue for both Gram-negative P. aeruginosa [3,4] and
Gram-positive pathogens such as Staphylococcus aureus [5] and
various streptococci [6]. To more effectively manage bacterial
infections associated with CF and other diseases such as COPD
and pneumonias, there is a critical need for next generation
antibiotics capable of treating drug-resistant pathogens. In one
approach to new therapies, genetically engineered antimicrobial
proteins are being developed based on knowledge of the
mechanisms by which innate immune factors sometimes fail.
Human lysozyme (hLYS) kills bacteria by catalytic hydrolysis of
cell wall peptidoglycan, but also exhibits catalysis-independent
antimicrobial properties [7]. Its dual functions result in a protein
that attacks both Gram-positive and Gram-negative bacterial
pathogens, and hLYS has been shown to be the most effective
cationic anti-pseudomonal agent in human airway fluids [8,9]. In
principle, this antimicrobial profile suggests that recombinant
hLYS could serve as a potent, protein therapeutic if delivered to
the airway using inhalation technologies such as those developed
for the FDA-approved, DNA-degrading enzyme Pulmozyme [10].
However, the failure of endogenous hLYS to effectively clear
bacteria during chronic infections indicates that the wild type
sequence suffers from some specific dysfunction in the infected
lung environment. Understanding and mitigating the inherent
functional limitations of wild type hLYS could facilitate develop-
ment of novel, antimicrobial, enzyme therapies.
The cationic nature of hLYS is thought to play an important
role in guiding the protein to the negatively charged surface of
bacteria. The dense positive charge of hLYS, however, also
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represents an Achilles’ heel, as the wild type enzyme can be
sequestered and inactivated by alginate [11], a biofilm matrix
component associated with mucoid P. aeruginosa lung infections
[12]. Furthermore, lower respiratory tract infections drive a
hyperinflammatory immune response, and subsequently cause the
local accumulation of additional, densely charged, anionic
biopolymers including F-actin, DNA, and mucin [13,14]. In the
infected lung, these biopolymers may exceed 1% wt/vol.
Concentrated polyanions radically alter the electrostatic environ-
ment of airway surface liquid, and are thought to inhibit various
cationic antimicrobial peptides and proteins [15]. This type of
electrostatic sequestration has been experimentally demonstrated
with hen egg white lysozyme [16], and variants of T4 phage
lysozyme having fewer cationic residues exhibit a reduced
propensity to complex with F-actin while retaining ,50%
antibacterial activity in phosphate buffered saline (PBS) [17].
Building upon these studies, we sought to develop genetically
engineered lysozyme variants designed specifically for high level
activity in the presence of various disease-associated, anionic
biopolymers, and against both Gram-negative and Gram-positive
bacterial species.
Results and Discussion
Enhanced Catalytic Function
In an effort to reduce the immunogenic potential of our
prospective therapeutic enzymes, we employed a human protein
scaffold as a starting template. Combinatorial libraries of charge
engineered hLYS variants were designed using bioinformatics and
structural analysis, and approximately 150,000 mutated enzymes
were screened for bacteriolytic activity in the presence of
inhibitory alginate polyanion. Among other functionally enhanced
enzymes, the Arg101RAsp and Arg115RHis double mutant was
found to lyse bacteria effectively at alginate, mucin and DNA
concentrations that inactivated wild type hLYS. Moreover, in the
absence of inhibitory biopolymers, the mutations did not
substantially impair the enzyme’s Vmax or Km, had no effect on its
in vitro anti-pseudomonal activity, and did not reduce lytic function
[11]. Indeed, time course killing assays in a standard lysozyme
activity buffer (66 mM phosphate, pH 6.24) revealed that the
double mutant’s non-inhibited kinetics were faster than those of
wild type hLYS [11]. More recently, we have extended the
inhibition assays to include actin, which is known to be a key
inhibitor of therapeutic proteins relevant to lung infections
[14,17]. In these studies, we chose to focus on the Gram-positive
lytic activity of hLYS, and we therefore employed the model
organism Micrococcus luteus. Our kinetic analysis is the first direct,
experimental demonstration that charge engineering can enhance
lysozyme activity in the presence of inhibitory F-actin (Fig. 1). Thus,
combinatorial mutation of hLYS combined with high throughput
functional screening generated an enzyme variant with decreased
net charge, reduced susceptibility to anionic biopolymer inhibi-
tion, and no loss of intrinsic bacteriolytic activity.
Structural and Sequence Analysis
To gain molecular level insight into the double mutant’s
enhanced function, we determined the protein’s X-ray crystal
structure. Analysis of the Matthews coefficient [18] suggests that
there are 2 molecules per asymmetric unit, with a VM value of
2.33 A˚3 Da21. We selected a mutation-free hLYS structure,
1LZS, as a search model for molecular replacement studies, and
subsequently identified a clear solution containing two protomers.
To avoid model bias associated with the high degree of sequence
identity between the wild type protein and the double mutant
(98.5%), iterative-build composite omit maps were calculated
(Fig. 2). The high quality electron density permitted direct
modeling of the initial molecular replacement solution. The
mutant residues at positions 101 and 115 of the protein sequence
search model were initially defined as alanine residues. Side chains
for Asp101 and His115 were substituted only after observing clear
electron densities at the respective positions. Iterative model
building and refinement to 2.04 A˚ resolution yielded a unit cell
containing 2050 atoms in two protein chains and 237 water
molecules, which was in excellent agreement with experimental
diffraction data (Table 1).
The Arg101RAsp and Arg115RHis mutations result in
minimal perturbation of the global enzyme structure, as
demonstrated by a superposition of the double mutant model
Figure 1. Lysozyme Inhibition by F-actin. In the absence of
inhibitor, the double mutant lyses bacteria at a rate equivalent to wild
type hLYS, but in the presence of inhibitory F-actin the kinetics of the
engineered enzyme are 2-fold faster (p = 0.001, two tailed t-test).
doi:10.1371/journal.pone.0016788.g001
Figure 2. Experimental Electron Density for the Double Mutant
Lysozyme. (Top Panels) Iterative Build Composite Omit Maps used for
initial model building. (a) Observed electron density for residue 101 and
neighboring residue Tyr20 shown as blue wire mesh. (b) Observed
density for residue 115 and neighboring residue Trp34. Residues are
shown as stick figures placed in the electron density omit maps:
Carbon-grey; Nitrogen-blue; Oxygen-red. The amino acids were placed
in the model when clear electron density was observed at these
positions in the omit map. (Bottom Panels) Final refined electron
density maps for (c) Asp101 & Tyr20 and (d) His115 & Trp34. Figure
rendered with CHIMERA [31].
doi:10.1371/journal.pone.0016788.g002
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onto the crystal structure of wild type hLYS (Fig. 3a). The mutated
residues are situated at opposite ends of the substrate-binding
groove, and as a result they have little impact on the catalytic core
of the active site (Fig. 3b). Both mutated residues are stabilized by
conformation specific interactions with native amino acids that are
adjacent in space but distant in the primary sequence. The mutant
Asp101 side chain forms an electrostatic N-O bridge [19] with
Arg21, and is within hydrogen bonding distance of Tyr20 (Fig. 4a).
Although the wild-type Arg101 side chain also forms a hydrogen
bond with Tyr20, it does so with a geometry different from the
mutant Asp101. Even more striking, repulsive charge-charge
interactions cause the wild type Arg101 and neighboring Arg21
side chains to orient away from each other (Fig. 4b). At the second
mutation site, the His115 side chain lies alongside Trp34 in a
parallel displaced p-stacking interaction [20] (Fig. 2d). This
orientation is similar to that of the wild type Arg115 side chain,
and reproduces an interaction found among natural lysozymes
having a histidine at this position, e.g. see canine milk lysozyme
(PDB code 1QQY [21]).
A Consurf bioinformatics analysis [22] of 50, naturally
occurring, C-type lysozyme orthologs was crucial in the develop-
ment of the highly active double mutant [11], and a close
examination of the results places the two performance-enhancing
mutations within the context of natural lysozyme sequences. Using
a multiple sequence alignment generated with the MUSCLE
algorithm [23] (Fig. S1), the natural sequence variability of
individual amino acid positions was assessed for the 50 lysozyme
orthologs. A normalized evolutionary conservation score was then
calculated for each of hLYS’s 130 residues. The most highly
conserved 25% of residues scored between 21.026 and 20.906,
whereas the most poorly conserved 25% of residues scored
between 0.589 and 2.811 (Fig. S2). In the multiple sequence
alignment, residue 101 is occupied by an arginine in 24 cases, a
serine in 24 cases, and a leucine or gap in the remaining two
enzymes (Fig. S1). Despite the limited amino acid diversity at
position 101, the lack of a clear consensus translates to a low
degree of evolutionary conservation (normalized score = 0.895,
least-conserved quartile). Significantly, the Asp101 side chain of
our highly active double mutant forms multiple stabilizing
interactions with neighboring amino acids (Fig. 4a), even though
this residue does not naturally occur at position 101 among
orthologs of our bioinformatics analysis (Fig. S1).
In contrast to position 101, position 115 was a consensus
histidine in 38 of the lysozyme orthologs. In addition to the 38
enzymes possessing a consensus histidine, four orthologs encode
Lys115, four Arg115, two Trp115, one Asn115, and one Gln115
(Fig. S1). The comparatively large stereochemical diversity among
alternative residues at this site resulted in a low degree of
evolutionary conservation (normalized score = 0.733, least-con-
served quartile) similar to that of position 101. Notably, our highly
active double mutant substitutes the wild type Arg115 with a
consensus histidine. It is therefore not surprising that the mutant
His115 side chain exhibits an energetically favorable interaction
with at least one neighboring side chain (Fig. 2d).
Electrostatic Potential Analysis
The propensity for wild type hLYS to complex with and be
inhibited by anionic biopolymers is due in large part to Coulombic
interactions, and as expected the functionally enhanced double
mutant has reduced cationic character. The calculated isoelectric
point of wild type hLYS is 9.3, and its predicted net charge at
neutral pH is +7.8 (Vector NTI sequence analysis software,
Invitrogen, Carlsbad, CA). The corresponding values of the
double mutant are 8.9 and +4.9, respectively. Thus, the two
mutations should result in a substantial reduction in net charge
near physiological pH, although the proteins were not clearly
resolved on pH 3–10 isoelectric focusing gels (data not shown). To
visualize the basis for the double mutant’s enhanced performance
in greater detail, we calculated the molecule’s electrostatic
potential field and compared the result to an identical analysis of
the wild type structure. Consistent with the net charge shift, the
overall strength of the double mutant’s potential field is
substantially decreased relative to wild type hLYS. At the same
time, the two mutations manifest an expanded negative potential
field in and around the substrate binding cleft (compare Fig. 3c
and 3d). Despite these considerable changes, small portions of the
double mutant’s positive potential field have been maintained at
wild type strength.
Stability Analysis
The structural stability of therapeutic proteins can play a key
role in (i) preventing aggregation during storage and (ii) enhancing
efficacy by preventing in vivo degradation. We therefore sought to
assess the extent to which the Arg101RAsp and Arg115RHis
mutations influenced lysozyme stability. Thermal denaturation
studies of the double mutant and wild type enzymes were
conducted by differential scanning fluorimetry [24]. In PBS
pH 7.4, wild type hLYS had a Tm = 63.760.6uC and the
engineered double mutant had a Tm = 63.860.7uC. Thus, the
two mutations had no significant effect on the engineered
enzyme’s thermal stability (p = 0.45).
Table 1. Data Collection and Refinement Statistics.
Data Collection
Space Group P212121
Unit Cell Parameters (A˚, u) 42.42 63.79 111.08, 90 90 90
Matthews coefficient (A˚3/Da) 2.33
Solvent content (%) 46.9
Resolutiona 19.86–2.04 (2.14–2.04)
Total reflectionsa 134735 (16297)
Unique reflectionsa 19829 (2606)
Rsym (%)
ab 6.5 (18.6)
Completenessa(%) 99.7 (99.5)
I/sIa 21.6 (9.5)
Refinement Statistics
# protein atoms (non-H) 2050
# waters 237
Rwork (%)
a 18.1 (17.7)
Rfree (%)
a 22.2 (22.9)
Ramachandran plotc (%) 97.7/2.3/0
RMSD (Bonds/Angles) (A˚, u) 0.008/1.014
Average Isotropic B-factors (A˚2)
Main chain (A/B)d 14.91/15.08
Side Chain (A/B)d 18.36/17.64
Waters 22.43
aValues in parentheses indicate statistics for the highest resolution shell of data;
bRsym =Shj|Iˆh2Ihj|/ShjIhj;
cFavored/allowed/outliers;
dResidual B factors (does not include the contribution to atomic displacements
from translation, libration and screw-rotation displacement).
doi:10.1371/journal.pone.0016788.t001
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Figure 3. Structural Comparison of Double Mutant and Wild Type hLYS. (a) Overlaid ribbon diagrams of the peptide backbones; wild type
hLYS in blue (PDB file 1JWR) [32] and charge engineered double mutant in red (PDB file 3LN2). The catalytic residues (35 and 53) and the two mutated
residues of 3LN2 (101 and 115) are shown as stick models with: Carbon-grey; Hydrogen-white; Nitrogen-blue; Oxygen-red. The structural alignment
yielded a low root-mean-squared (RMS) deviation of 0.42 A˚ for the backbone atoms and 1.17 A˚ overall. (b) Detailed view of the active site indicating
negligible differences in the position of the catalytic residues Glu35 and Asp53. (c) The electrostatic potential field of wild type hLYS contoured as a
110 kJ/mol surface. Calculation performed with the AMBER99 force field in an 83670677 A˚ simulation cell with periodic boundaries. Positive
potential is colored dark blue and negative potential red. The peptide backbone is rendered as a yellow ribbon, and the substrate binding cleft is
indicated with a light blue line. The field is overwhelmingly positive in nature with negative potential localized predominantly near the catalytic
residues Glu35 and Asp53. (d) The analogous electrostatic potential field of the double mutant contoured at 110 kJ/mol. The global electrostatic field
is contracted relative to the wild type protein, as seen by the reduced size of the 110 kJ/mol surface. Additionally, the potential of the active site cleft
has been extensively remodeled, and exhibits several expanded regions of negative potential. A small region of positive potential at the upper lip of
the active site cleft is maintained at wild type strength (blue lobe at left), as is a larger portion of positive potential distal to the active site cleft
(protruding lobe at far right of image). Calculations performed and images rendered with YASARA Structure v9.10.5.
doi:10.1371/journal.pone.0016788.g003
Figure 4. Residue 101 Interaction Analysis. A partial ribbon diagram of the peptide backbone is shown with neighboring side chains rendered
as stick figures. Residue 101 and interacting partners are differentially colored: Carbon-grey; Hydrogen-white; Nitrogen-blue; Oxygen-red. (a) The local
environment of Asp101 in the double mutant structure (PDB file 3LN2). At image center, a carboxylate oxygen of Asp101 is 3.36 A˚ from a guanidino
amine of Arg21 resulting in an electrostatic N-O bridge (green line) [19]. At the same time, the Asp101 side chain is within hydrogen bonding distance
of Tyr20’s phenolic group (broken yellow line, 2.67 A˚ O-O distance). (b) The local environment of Arg101 in wild type hLYS (PDB file 1JWR) [32]. At
image center, the wild type Arg101 is able to hydrogen bond with Tyr20 (broken yellow line, 2.92 A˚ N-O distance), but orients away from Arg21 as a
result of electrostatic repulsion. Images rendered with YASARA Structure v9.10.5.
doi:10.1371/journal.pone.0016788.g004
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In addition to thermal stability, resistance to human neutrophil
proteases is an important parameter for pulmonary biotherapies,
as neutrophil derived proteases can accumulate to micromolar
concentrations in the infected and inflamed lung [25]. We
therefore assessed proteolysis of the double mutant and wild type
hLYS by human neutrophil elastase, cathepsin G, and proteinase
3. Our analysis shows that neither enzyme is susceptible to
degradation by physiologically relevant concentrations of the three
neutrophil proteases (Fig. 5). Combined with the thermal
denaturation studies, these results indicate that the Arg101RAsp
and Arg115RHis mutations do not alter the double mutant’s
structural stability relative to wild type hLYS.
Conclusion
The double mutant detailed in this manuscript is not the only
functionally enhanced enzyme to be isolated in the course of large
combinatorial library screens. More than 30 different charge
modified variants having diverse sequences, net charges, and
charge distributions were found to exhibit greater lytic activity
than wild type hLYS in the presence of inhibitory alginate
biopolymer [11]. The Arg101RAsp and Arg115RHis double
mutant, however, is the only variant thus far proven to retain wild
type or better lytic activity in the absence of inhibitory biopolymers
(Fig. 1). This observation underscores the complex interplay
between hLYS charge distribution and bacteriolytic function, and
it suggests that specific regions of stereochemical conservation are
key to engineering lysozymes with high level activity in both
inhibitory and non-inhibitory conditions.
In summary, we have engineered the first lysozyme protein
specifically designed for enhanced function in the presence of
disease-associated, anionic biopolymers. This biotherapeutic
candidate kills both Gram-negative (P. aeruginosa) and Gram-
positive (M. luteus) bacteria more efficiently than the wild type
protein under inhibitory conditions, and our structural analysis
indicates that a reshaped electrostatic potential field underlies its
enhanced antibacterial properties. The substituted amino acids of
the variant enzyme exhibit energetically favorable interactions
with spatially adjacent amino acids, and as a result the global
structure and stability of the variant are equivalent to those of the
wild type protein. While the charge engineered hLYS variant is
particularly relevant to CF-associated bacterial infections, its
broad spectrum utility may ultimately extend to other chronic or
acute lung infections resulting from COPD, hospital acquired
pneumonia or community acquired pneumonia.
Materials and Methods
Recombinant hLYS, freeze-dried M. luteus, and SYPRO
Orange 50006Protein Stain were purchased from Sigma-Aldrich
(St. Louis, MO). MicroAmpH Fast Optical 0.1 ml 96-Well Plates
and MicroAmpH Optical Adhesive Film were from Applied
Biosystems (Bedford, MA). Human neutrophil elastase, human
neutrophil cathepsin G, and human neutrophil proteinase 3 were
from Athens Research & Technology (Athens, GA). Rabbit muscle
G-actin was a kind gift from Dr. Henry N. Higgs and Ernest G.
Heimsath, Jr. of Dartmouth College. All other chemicals and
reagents were purchased from Fisher Scientific (Pittsburgh, PA).
Lysozyme Inhibition Assay
Time course lysis of Micrococcus luteus bacteria was monitored by
light scattering at 450 nm, and specific rates of lysis with and
without F-actin are reported. Light scattering was monitored in
clear bottom 96-well plates on a Molecular Devices SpectraMax
190 UV/Vis microplate spectrophotometer. Non-inhibited reac-
tions contained 300 mg/ml M. luteus and 200 ng/ml lysozyme in
150 ml of 5 mM Tris pH 7.0. Reactions with F-actin were
assembled as follows: 120 ml solutions of rabbit muscle G-actin
were polymerized by agitating at 25uC for 15 minutes in 50 mM
KCl, 2 mM MgCl2, 0.2 mM CaCl2, 1 mM ATP, and 5 mM Tris
pH 7.0. Thirty nanograms of purified lysozyme in 5 ml of 5 mM
Tris pH 7.0 were then added to the F-actin solutions, and
agitation was continued for an additional 20 minutes. Lytic
reactions were initiated by adding 25 ml of 1.8 mg/ml M. luteus
stock solution. The final actin concentration in the lytic reactions
was 836 mg/ml. All lytic rates were determined from slopes of the
initial, linear portions of light scattering vs. time data. Reactions
were performed in triplicate, and repeated experiments yielded
essentially identical results. The double mutant kinetics were also
2-fold faster than wild type hLYS in F-actin reactions containing
333 ng/ml lysozyme (data not shown).
Thermal Denaturation Studies
Differential Scanning Fluorimetry was performed essentially as
described [24] using an ABI 7500 Fast Real-Time PCR System
from Applied Biosystems (Bedford, MA). Proteins and SYPRO
Orange were diluted in PBS. Final protein concentrations were
100 mg/ml and 50 mg/ml, and final dye concentrations were 206,
106, and 56. Twenty ml reactions of all conditions (6 per protein)
were performed in triplicate. The PCR gradient was run from 25–
94uC with a 1 minute equilibration at each degree. Fluorescence
was quantified using the preset TAMRA parameters. Melting
temperatures were determined by data analysis with the ‘‘DSF
Analysis v3.0.xlsx’’ Excel sheet (ftp://ftp.sgc.ox.ac.uk/pub/bio-
physics/) and GraphPad Prism v. 4 software (La Jolla, CA).
Proteolytic Sensitivity Assays
Wild type hLYS, the purified double mutant, or BSA were
diluted to 90 ng/ml in 10 ml reactions containing either elastase,
cathepsin G, or proteinase 3. Three final protease concentrations
Figure 5. Proteolytic Susceptibility Analysis of Lysozymes. An
SDS-PAGE gel was Coomassie stained for total protein. Lane
1 = Kaleidoscope prestained molecular weight standards. Lanes 2–
5 = 900 ng of the engineered double mutant. Lane 2 is an untreated
control, and lanes 3, 4, and 5 are 50 mg/ml treatments with human
neutrophil elastase, cathepsin G, and proteinase 3, respectively. Lanes
6–9 are the wild type hLYS arrayed in a similar fashion. Lanes 10–13 are
bovine serum albumin (BSA) arrayed in a similar fashion. The wild type
hLYS and engineered double mutant migrate just below the 15 kDa
band as expected (lanes 2–9). The BSA control migrates between the 50
and 75 kDa bands as expected (lane 10). The three proteases can be
seen migrating between the 25 and 37 kDa bands in the treatment
lanes. Neither wild type hLYS nor the double mutant is degraded by the
proteases, while BSA is fully degraded by all three. Similar results were
obtained with both 5 mg/ml and 0.5 mg/ml protease treatments (data
not shown), although BSA was only partially degraded by 0.5 mg/ml
proteinase 3.
doi:10.1371/journal.pone.0016788.g005
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were examined: 0.5 ng/ml, 5 ng/ml, and 50 ng/ml. All assays were
conducted in PBS pH 7.4. Reactions were incubated for 3 hours
at 37uC, and the products were immediately analyzed on 15%
reducing, denaturing, SDS-PAGE gels. Bands were visualized with
Code Blue gel stain.
Crystallization and Data Collection
The isolation, expression, and purification of the mutated
protein has been described in detail elsewhere [11]. Purified
protein was dialyzed against crystallization buffer (10 mM
KHPO4 pH 6.0, 100 mM NaCl) and concentrated to 7.0 mg/
ml by centrifugal ultrafiltration. The protein was crystallized by 3–
4 days of vapor diffusion against 20 mM sodium acetate pH 4.3,
and 1.25 M NaCl at 18uC. The resulting crystals were
cryoprotected by washing in mineral oil followed by soaking in
well solution supplemented with 20% Ethylene Glycol. A complete
dataset was collected for a single crystal at 100 K on a MAR345
image plate system using Cu Ka radiation produced with a
rotating anode (Rigaku) equipped with focusing mirrors (Xenocs
FOX-2D) and a Crystal Cryocooler (Cryo Industries).
Model Building and Refinement
Data reduction, indexing, integration and scaling were done
using programs of the XDS package [26]. Since the protein crystal
exhibited non-crystallographic symmetry (NCS), the Rfree set was
selected in thin shells using the program SFTOOLS of the CCP4
package [27], and the same Rfree dataset was used throughout
refinement. Owing to the availability of numerous homologous
hLYS structures, we used molecular replacement to obtain the
initial phases. Wild type hLYS (PDB code: 1LZS [28]) was
employed as a search model in the AutoMR program of the
PHENIX software suite [29]. A clear solution was found with a
log-likelihood gain of 2508 and a solvent content of 46.9%, as
determined from the Matthew’s coefficient calculation. The
AutoBuild module of the PHENIX suite was used to calculate a
density-modified, NCS-averaged, solvent-flattened, histogram-
matched, iterative build omit map, and the initial model was
built into this omit map manually using the program COOT [30].
The solution was then subjected to multiple rounds of refinement
using the Refine module of PHENIX. This process included rigid
body refinement, individual and grouped B-factor refinement, and
NCS averaging. When the model was well-refined, water
molecules were picked and refined. Any water molecules
exhibiting weak electron density or instability during refinement
were subsequently discarded. TLS refinement using each chain as
a TLS group was carried out in the final stages of refinement.
Protein Databank accession number
The atomic coordinates and structure factors of the double
mutant have been deposited in the Protein Data Bank under
accession number 3LN2.
Supporting Information
Figure S1 Multiple Sequence Alignment Generated by
Consurf Analysis of PDB file 1LZS. Wild type hLYS is the
first sequence. Identical residues in the other lysozyme orthologs
are noted with periods, and gaps are noted with dashes. Residues
101 and 115, the sites of mutation in this study, are boxed in red.
(PDF)
Figure S2 Distribution of Consurf Evolutionary Con-
servation Scores for the Residues of Wild Type hLYS. A
bioinformatics analysis was conducted on PDB file 1LZS using the
Consurf web server. The analysis generated position specific
evolutionary conservation scores for each of the protein’s 130
amino acids. Larger negative scores were assigned to highly
conserved residues and larger positive scores to poorly conserved
residues. The histogram shows the distribution of conservation
scores for the entire hLYS sequence. The most poorly conserved
25% of residues scored between 0.59 and 2.81 (noted by bracket).
Residues 101 and 115, the sites of mutation in the engineered
variant, scored 0.895 and 0.733, respectively.
(TIF)
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